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Werner Solbach, Heidrun Moll and 
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Macrophages as hosts for microbes 
The fate of intracellular parasites 
is strongly influenced by their mech-
anis m of attachment to, and pen-
etration of, host cells. Toxoplasma 
gondii tachyzoites, for example, can 
either actively invade their host and 
survive or can be phagocytosed and 
arekilled (K.Joiner, New Haven). In 
the former case, laminin adsorbed to 
the tachyzoite surface binds to the 
integrin-ßl receptors on the cell 
surface. Entering via this route, 
T oxoplasma take up residence in 
vacuoles that exdude host mem-
brane glycoproteins. Such vacuoles 
fail to fuse with acidifying lysosomes 
and endosomes thus protecting the 
parasites from lethaI host responses. 
However, jf the tachyzoites are 
coated with antibody, they are 
bound by macrophage Fc receptors 
(FcR); the blocks in fusion and acidi-
fication of the vacuoles are overcome 
and the microbes are killed by trig-
gering the macrophage's respiratory 
burst. The mechanism of this FcR-
mediated reversal of the block in 
fusion and acidification is not yet 
dear but studies using respiratory-
burst-negative ceIls transfected with 
various FcR mutants have shown 
that distinct domains of the cyto-
plasmic tail of the FcR direct endo-
cytosis and phagocytosis. 
Leishmania adopt a different en-
try and survival strategy. They pass-
ively attach to various receptors, 
including complement receptors, on 
the host cell surface by means of 
lipophosphoglycan and gp63 and 
are taken up by conventional 
phagocytosis. Leishmania-conraining 
phagosomes fuse effectively with 
lysosomes, as shown by the presence 
of lysosomal enzymes within the 
parasitophorous vacuole (D. RusselI; 
St Louis) and kinetic studies have 
revealed that a constant supply of 
lysosomal enzymes is likely to be 
released into these vacuoles. The 
Researchers interested in immunologi-
caJ aspects of bacterial, fungal, pro-
tozoan and helminthic infection are 
too often kept apart by artificial sub-
ject boundaries. These barriers were 
temporarily breached by arecent 
workshop * in which the comp/ex in-
terplay between microbes and their 
mammalian hosts were examined (rom 
aglobai viewpoint. The role of T-cell 
subsets and their products came under 
dose scrutiny but the most forceful 
image was that of the macrophage. As 
host for infective agents, as modulator 
of specific immune activity and as ulti-
mate mediator of the host response, 
the macrophage plays a virtuoso's role 
in the host-parasite drama. 
magnitude of the respiratory burst 
is decreased when triggered by 
complement-coated parasites, so 
that the mechanism of entry may 
contribute in more than one way to 
the survival of the parasite. 
Macrophages as antigen-presenting 
cells (APCs) 
Two major pathways have 
evolved for the presentation of anti-
gen to T cells. Intracellular antigens 
are mainly processed in the cytosol 
and are presented in the context of 
MHC dass I molecules, whereas ex-
ogenous antigens are generally pro-
cessed by the endosomal pathway 
and associate with MHC dass 11 
molecules. P. Kaye (London), work-
ing with Leishmania donovani, 
showed that phagolysosomes of 
infected macrophages contain para-
sites in various stages of degra-
dation. Although MHC dass 11 mol-
ecules could be seen within the 
phagolysosomes, they are not used 
*The Fourth International Erlangen 
Workshop on Moleeular Aspects of Im-
munological Host-Parasite Interactions 
was held at Erlangen, FRG on 27-29 
September 1990. It was organized by M. 
Röllinghoff, W. Solbach and J. Kalden. 
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for antigen presentation: the meta-
bolie inhibitor Brefeldin-A abro-
ga ted the presentation of parasite 
antigens to MHC dass-II-restricted 
T cells. Brefeldin-A blocks the trans-
port of newly synthesized proteins 
from the endoplasmic reticulum to 
the Golgi apparatus, suggesting that 
only nascent MHC molecules are 
used by APCs. 
The macrophage as an APC plays 
a key role in determining whether or 
not a cellular immune response pro-
motes protection of the host or sur-
vival of the infectious agent. One 
important factor is the level of ex-
pression of MHC molecuJes; as 
an illustration of this, H-D. Volk 
(Berlin) showed data demonstrating 
that in patients with septicemia there 
is a dose association between re-
duction in monocyte HLA-DR ex-
pression and fatal outcome. 
MHC antigen expression is modu-
lated by T-cell-derived cytokines but 
can also be profoundly influenced 
by the natural resistance gene Beg 
(which is probably identical to lty 
and Lsh). Beg is located on mouse 
chromosome 1 and, presumably, on 
human chromosome 2q, within a set 
of genes coding for cytoskeletal pro-
teins (E. Skarnene, Montreal). In its 
two allelic forms Beg confers resist-
ance and susceptibility to infee-
tion with Salmonella typhimurium, 
Leishmania donovani, mycobacteria 
and other macrophagic parasites 
in mice and preliminary studies in 
humans suggest a similar dichot-
omy. The Beg gene product, in ad-
dition to controlling MHC dass 11 
antigen expression, affects 5' nu-
deotidase activation, the respiratory 
burst and expression of the ligand 
for AcM.l, an antibody that recog-
nizes activated macrophagcs. 
MHC molecules direct the im-
mune system towards responses me-
dia ted largely by either CD4 + or 
CD8+ T cells and this may be partly 
controlled by the site of intersection 
of MHC molecules and peptide. 
Thus infected macrophages may 
present a distinct set of peptides, and 
induce a response of different em-
phasis to that induced by uninfected 
macrophages that acquire locally-
available peptides by endocytosis. 
The suggestion by J. Louis 
(Lausanne) that live and dead para-
sites induce different T -cell subsets is 
in agreement with this possibility. 
The divergent responses induced 
may be synergistic: in cutaneous 
leishmaniasis, resistance to disease is 
induced by CD4 + cells without the 
requirement for CD8+ cells. How-
ever, CD8+ cells enhance the de-
velopment of resistance by their 
ability to produce gamma-interferon 
(IFN--y) (Louis) and an optimal bal-
ance between the two subsets may be 
required for maximal protection, as 
was found by M.A. Mielke (Berlin) 
for listeriosis and brucellosis. 
A different way of stimulating T 
cells is used by staphylococcal en-
terotoxins (SE). The mitogenic T -cell 
response induced by these and other 
'superantigens' is dependent on 
MHC dass II molecules present on 
APCs but is not MHC-restricted and 
does not require processing. Differ-
ent SEs lead to the preferential ex-
pansion of T cells expressing a 
particular V wencoded gene segment 
of the T-cell receptor (TCR). Ir has 
been suggested that the SE, TCR and 
MHC dass II molecules form a tri-
molecular complex with bivalent SE 
crosslinking variable parts of the 
TCR and conserved regions of MHC 
moleeules (B. Fleischer, Mainz; C. 
Janeway, New Haven). An alterna-
tive model for SE action was pro-
posed by C. Janeway: SE may alter a 
putative endogenous co-Iigand in a 
way that it crosslinks V ß of the TCR 
and MHC molecules sufficiently to 
activate a T cell. The endogenous 
equivalents of superantigens in mice, 
the products of the Mis locu5, may be 
anormal constituent of cellinter-
actions. 
The complex mechanisms govern-
ing processing, presentation and rec-
ognition make the question oi what 
characterizes a T -cell antigen diffi-
cult to answer. Several studies have 
suggested that T-cell antigens need 
not necessarily be proteins. For 
example, in mice, lipophospho-
glyean from L. major induees pro-
tection that can be transferred by 
CD4 + T cells (H. Moll, Erlangen) 
and human T eells bearing the rS-
T-cdl receptor can respond to myco-
bacterial components that are re-
sistant to protease digestion (K. 
Pfeffer, Munieh). 
Macrophages as anri-microbial 
effector cells 
To destroy invading organisms 
macrophages need to convert from a 
state that sustains intracellular repli-
cation of microbes to an activated 
state. C. Nathan (New York) sum-
marized reeent progress in the 
understanding of thc proccsses regu-
lating macrophage activation, par-
ticularly the biochemical pathways 
that may be used to generate toxie 
reactive oxygen and nitrogen inter-
mediates (ROI; RN!). RNI can be 
regarded as sequential intermediates 
in the oxidation of a guanido-
nitrogen trom L-arginine to nitrate. 
The microbial target molecules for 
RN! have yet to be identified but it 
seems likely that they will be found 
in metabolie pathways such as e1ec-
tron transport chains, the tricarb-
oxylic acid cyde and DNA synthesis. 
The list of cytokines acring on 
macrophages to induce ROI and 
RNI and otherwise enhancing 
anti-microbial activity is long and 
indudes granulocyte-macrophage 
colony-stimulating factor (GM-
CSF) and tumour necrosis facror-a 
(TNF-a). These powerful mediators 
must be carefully controlIed: e1ev-
ated and sustained production of 
TNF-a correlates with the severity 
of a number of infectious diseases, 
including shock in bacterial sepsis, 
although TNF-a seems to have a 
beneficial role when produced 10-
cally and transiently. V. Kindler 
(Geneva), for example, showed in 
ex vivo studies that, in mice infected 
with BCG, TNF-ct is synthesized 10-
eally at the site of inflammation and 
is essential for granuloma forma-
tion and antibacterial macrophage 
activation. M-L. Lohmann-Matthes 
(Hannover) reported that TNF-ct 
acts not only in soluble form but 
also, and perhaps more importantly 
to 10cal activity, as a membrane-
associated molecule. 
Dealing with a single cytokine 
on an isolated population of reHs 
may be a gross oversimplification 
of events in viva, as essenrially 
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all macrophage-activating cytokines 
are produced at low concentrations 
during an ongoing infection. W. Sol-
bach (Erlangen) showed that TNF-ct 
and interleukin 4 (IL-4) in low con-
centrations independently synergize 
with IFN--y for macrophage acti-
vation whereas none of these 
cytokines was very effective as a 
single agent. The cell activation in-
duced by the combination of ILA 
and IFN-"{ could be blocked com-
pietely using antibodies to TNF-ct 
and Sol bach, therefore, proposed 
that ILA combined with IFN--y in-
duces the production of TNF-a by 
macrophages; TNF-a then syner-
gizes with IFN-"{ to activate the cells 
for anti-parasite activity. 
Since the results of macrophage 
acrivation are potentially detrimen-
tal to the host, it is not surprising 
that soluble factors that deactivate 
macrophages have been discovered. 
Exciting work from Nathan's 
group has attributed this activity 
to macrophage-deactivating factor 
(MDF) and transforming growth 
factor ~ (TGF-ß). MDF, a 13 kDa 
protein, has been purified to hom-
ogeneity and apparently interferes 
wirh ROI production by reducing 
the affinity of the enzyme 
NADPH:02 oxidoreductase for the 
co-substrate NADPH. MDF is dis-
tinet from TGF-ß since neither the 
antibodies nor the cell surface recep-
tors that bind TGF-ß recognize 
MDF. 
Vaccination and treatment 
Several speakers discussed the im-
plications of recent findings for vac-
cination prophylaxis and treatment 
of infections. A. Sher (Bethesda) re-
ca lied that live attenuated vaccines 
usually induce a better level of 
proteetion than purified or recom-
binant immunogens. This was also 
testified to by R. Pink (Basel), K. 
Früh (Heidelberg) and B. Knapp 
(Marburg}, all of whom work 
on molecularly-defined immunogens 
from Plasmodium falciparum. 
Major differences between living 
and non-living vaccines are antigen 
persistence in the vaccinee and the 
inability, so far, to target non-living 
immunogens to macrophages in a 
form that induees a protective im-
mune response. 
Protective immune responses can 
be mediated by either CD4+ or 
CD8+ cells and in many cases are 
associated with high levels of IFN-'Y. 
A powerful vaccine may, therefore, 
consist of an attenuated living or-
ganism that acts as a persisting car-
rier of defined microbial immunogens 
from the infectious agent. It should 
induce an IFN-'Y-biased response 
and may even incorporate genes for 
'beneficial' cytokines or antagonists 
of 'detrimental' cytokines. Two in-
itiatives of this type were discussed. 
Sher reported on his success in vac-
cinating mice with live BCG that 
contained an integral schistosomal 
para myosin gene against schisto-
somiasis and E. Liew (Beckenharn) 
reported on mice immunized oraUy 
with mutant S. typhimurium 
(AroA -) that carried the gp63 gene 
of 1. major. This vaccine induced 
IFN-'Y production by CD4 + T cells 
and a partial resistance to infection. 
However, activation of IFN-'Y-
media ted responses alone may not 
always be sufficient to induce protec-
tion. J. Langhorne (Freiburg) clearly 
showed in mouse infections with 
Plasmodium chabaudi that, in ad-
dition to IFN-'Y, CD4+ T-cell-
dependent antibody production was 
essential for complete clearance of 
the pathogen. Conversely, the pres-
ence of high levels of IFN-'Y does 
not necessarily indicate protection 
(Louis). Vaccination against Lyme 
disease using the outer surface pro-
tein A (OspA) of Borre/ia burgdor-
(eri in duces a protective antibody 
response in mice (M. Simon, 
Freiburg) and the same antigen 
stimulates T cells from patients 
with Lyme arthritis (G. Burmester, 
Erlangen). Clearly the type of im-
mune response that gives optimal 
protection varies with the pathogen. 
For this reason a great deal more 
information on basic immune-
system-parasite interaction is re-
quired before optimized vaccine pro-
tocols can be developed. 
In addition to active immuniz-
ation, passive immunoenhancing 
therapy deserves attention in the fu-
ture. This approach has proved to be 
effective in trials of IFN-'Y and GM-
CSF. G. Kaplan (New York) is now 
assessing intradermal deposition of 
IL-2 into lesions of patients with lep-
romatous leprosy. Another strategy 
of intervention is the blockade of 
stimuli inducing detrimental TNF 
responses, as was successfully per-
formed in patients with Gram-
negative sepsis that were given anti-
bodies to lipopolysaccharide (LPS) 
(B. Baumgartner, Lausanne). A third 
strategy, that of blocking macro-
phage deactivation, will be used in 
the near future. 
Clearly vaccine development is an 
area of great interest and of con-
siderable, if as yet unfulfilled, po-
tential. The increasing awareness 
of host-parasite interactions will 
surely supply the momentum for 
further advancement in the near 
future. 
Werner Solbach, Heidrun Moll and 
Martin Röllinghoff are at the Institut 
für Klinische Mikrobiologie, Wasser-
turmstrasse 3, D-8520 Erlangen 3, 
FRG. 
Today's ImmunoJogy Today 
In this issue, the first of 1991, we 
launch a new look for Immunology 
Today. The aim of the redesign is 
first and foremost to make the 
journal more accessible to readers by 
simplifying the layout, improving 
the readability of the text and en-
hancing its appearance. To achieve 
this we have altered the section 
names, typeface and logo and intro-
duced a centered page layout and an 
elegant, dear typeface that is easy on 
the eye. 
One of the most noticeable and 
appealing changes is to the Contents 
page, which can now be found on 
page 3. The previous 'busy' arrange-
ment has been replaced by a much 
dearer, more functional design. Sec-
tion titles have also been altered. 
Trends, which replaces News and 
Features, will focus on new direc-
tions in immunological research 
with a combination of short, themed 
meeting reports and other major 
news stories. Another purpose of the 
redesign is to distinguish more 
dearly between speculative artides 
and review papers. With this in 
mind, and to reflect its content more 
accurately, the Rostrum section has 
been renamed Viewpoint. In every 
other respect it is unchanged: it will 
continue to be the forum for airing 
new hypotheses, debating contro-
versial topics and exploring the lead-
ing edges of immunology. Most of 
the articles will, as always, be 
suggested by readers. 
Concise, readable and informative 
reviews commissioned from leading 
researchers will remain at the heart 
of each issue. The timeliness and 
high quality of these articles have 
helped to make Immunology Today 
the most popular way for immu-
nologists to stay up to date with this 
exciting and fast-moving subject. 
Editorial pages have been in-
creased to 580 for 1991 and to make 
the most of this windfall for readers 
an entirely new section, Kaleido-
scope, has been introduced. As the 
name suggests, Kaleidoscope will 
contain a rieh variety of new artieies 
that will extend the scope of the 
journal. For example, in this issue 
the first of an occasional history 
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series, Immunology Yesterday, is 
featured. Future topics will include 
articles on national and inter-
national immunology organizations, 
a 'Good Journal Guide', book re-
view supplements, guidelines for sci-
ence writing and design of figures 
and insights into the application 
of immunology in industry. An 
expanded correspondence section, 
book reviews and the meetings diary 
will be regular components of 
Kaleidoscope. 
We would like to extend our 
thanks and congratulations to Sheila 
Betts (Graphie Design) who is re-
sponsible for the new look and to 
gratefully acknowledge the input 
of the Production Department of 
Elsevier Trends Journals, particu-
larly Judith Basrin, and of Susan 
Gatell, Marketing Manager. 
Comments on the content and 
suggestions for further improve-
ments to the design will always be 
welcomed. 
Richard B. Gallagher Editor 
Christine Doberska Assistant Editor 
